BB&T Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

BB&T Securities’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$401K	Buy	10,928 +1,778	+19%	+$53.9K	﹤0.01%	1192
2019 Q2	$244K	Sell	9,150 -2,001	-18%	-$51.1K	﹤0.01%	1422
2019 Q1	$299K	Buy	+11,151	New	+$260K	﹤0.01%	1296
2018 Q4	–	Sell	-17,049	Closed	-$353K	–	1475
2018 Q3	$353K	Sell	17,049 -1,569	-8%	-$24.7K	﹤0.01%	1256
2018 Q2	$284K	Buy	18,618 +3,613	+24%	+$64.4K	﹤0.01%	1304
2018 Q1	$337K	Buy	15,005 +2,347	+19%	+$65K	﹤0.01%	1191
2017 Q4	$381K	Buy	12,658 +7,295	+136%	+$233K	﹤0.01%	1091
2017 Q3	$202K	Sell	5,363 -5,540	-51%	-$180K	﹤0.01%	1295
2017 Q2	$304K	Buy	+10,903	New	+$325K	﹤0.01%	1140

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BB&T Securities's ACAD Position: Q3 2019 in Review

BB&T Securities increased its Acadia Pharmaceuticals (ACAD) stake by 19% in Q3 2019, buying an estimated $53.9K and bringing the position to 10,928 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

BB&T Securities first reported a position in ACAD in Q2 2017 and has held it in 9 quarters since. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

BB&T Securities held 10,928 shares of Acadia Pharmaceuticals worth $401K as of Q3 2019.
BB&T Securities bought 1,778 Acadia Pharmaceuticals shares in Q3 2019, an estimated $53.9K.
Acadia Pharmaceuticals made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1192 holding.
BB&T Securities first reported a position in Acadia Pharmaceuticals in Q2 2017 and has held it in 9 quarters since.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.